Table 1.
Baseline characteristics of patients
|
Characteristics
|
n
(%)/mean ± SD/M (P25-P75)
|
| Gender (male/female) | 70/13 (84.3/15.7) |
| Age (yr) | 56.46 ± 8.97 |
| BMI | 22.83 ± 2.99 |
| Etiology of cirrhosis (HBV/HCV/alcoholic/other) | 66/8/4/5 (79.5/9.6/4.8/6.0) |
| Cirrhosis-related decompensated events (EGVB/Refractory ascites or hydrothorax/Both) | 62/14/7 (74.7/16.9/8.4) |
| EGV degree (mild/moderate/severe) | 7/36/40 (8.4/43.4/48.2) |
| Ascites degree (no/mild/moderate-severe) | 8/24/51 (9.6/28.9/61.4) |
| Preoperative HVPG (mmHg) | 19.96 ± 9.01 |
| Child–Pugh grade (A/B/C) | 23/52/8 (27.7/62.7/9.6) |
| Intrahepatic HCC morphology (unifocal/multifocal) | 47/36 (56.6/43.4) |
| Sum of longest viable tumor diameters (cm) | 6.62 ± 2.77 |
| ≤ 5/5-8/> 8 | 23/44/16 (27.7/53.0/19.3) |
| BCLC stage (C/D) | 75/8 (90.4/9.6) |
| cTNM stage (IIIB/IVA/IVB) | 55/19/9 (66.3/22.9/10.8) |
| PLT (109/L) | 108.24 ± 86.09 |
| PT (s) | 14.89 ± 3.89 |
| ALT (U/L) | 31.40 ± 29.29 |
| AST (U/L) | 49.63 ± 45.00 |
| TBil (μmol/L) | 31.74 ± 17.68 |
| Albumin (g/L) | 35.08 ± 4.85 |
| AFP (ng/mL)1 | 769.49 (16.69-2345.11) |
| Log10(AFP) | 2.40 ± 1.26 |
| Combined TACE/RFA/targeted therapy | 83/52/41 (100/62.7/49.4) |
1
Skewness distribution. The upper limit of AFP detection is 20000 ng/mL. BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; EGVB: Esophagogastric variceal bleeding; EGV: Esophagogastric varices; HVPG: Hepatic venous pressure gradient; HCC: Hepatocellular carcinoma; PLT: Platelet; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBil: Total bilirubin; AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation.